Holen Sie sich die Stockscreener-App
0.453
3.90%
-0.0184
Schlusskurs vom Vortag:
$0.4714
Offen:
$0.4659
24-Stunden-Volumen:
286.26K
Relative Volume:
0.58
Marktkapitalisierung:
$12.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-55.73M
KGV:
-0.1404
EPS:
-3.2274
Netto-Cashflow:
$-68.87M
1W Leistung:
-2.79%
1M Leistung:
-43.83%
6M Leistung:
-75.65%
1J Leistung:
-91.39%
1-Tages-Spanne:
$0.4414
$0.4769
1-Wochen-Bereich:
$0.4308
$0.5205
52-Wochen-Spanne:
$0.42
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.453 | 12.69M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Fortgesetzt | UBS | Neutral |
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Jasper Therapeutics StockAnalyst consensus and weekly review - AD HOC NEWS
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPRW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jasper Therapeutics Inc (JSPRW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPRW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPRW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPRW) Institutional Confidence - TradingKey
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate - Dailyhunt
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
JSPR | Jasper Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Jasper Therapeutics (JSPR) Edges Lower, Testing Key Support Near $0.44FRAMA Signal - newsline.com
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
Jasper Therapeutics (JSPR) Edges Higher Amid Tight Trading RangeAndrews Pitchfork - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
JSPR Q1 2026 Earnings: Massive EPS Beat with -$0.04 vs -$0.4965 Estimate; Stock RisesEarnings Power Value - newsline.com
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long - Benzinga
Bears are losing control over Jasper Therapeutics (JSPR), here's why it's a 'buy' now - MSN
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - sharewise.com
Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value - marketscreener.com
Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives - Moomoo
Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain - BriefGlance
Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 - Minichart
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty - TipRanks
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com South Africa
Jasper Therapeutics explores strategic alternatives - Investing.com
Jasper Therapeutics begins strategic review to maximize shareholder value - TradingView
Jasper Therapeutics (NASDAQ: JSPR) weighs sale, merger or wind-down options - Stock Titan
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - GlobeNewswire
JSPR Q1 2026 Earnings: Surprise EPS Beat Overshadowed by Broader HeadwindsAnnual Financial Report - The Legal Advocate
JSPR Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Slides Despite ProgressProduct Revenue Analysis - newsline.com
Jasper Therapeutics (JSPR) Hovers Near Support as Biotech Sentiment Remains CautiousWave Equality - The Legal Advocate
Jasper Therapeutics (JSPR) Edges Higher: Small-Cap Biotech Tests Resistance at $0.95ETF Flow - The Legal Advocate
Jasper Therapeutics (JSPR) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - The Legal Advocate
Jasper Therapeutics Announces Board Resignation and Committee Change - TipRanks
Christian Nolet resigns from Jasper Therapeutics board; Svetlana Lucas joins Audit Committee - TradingView
Jasper Therapeutics (NASDAQ: JSPR) reports director exit and audit change - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGeovax Labs (NASDAQ:GOVX), Jasper Therapeu - Benzinga
Jasper Therapeutics, Inc.Class A Common Stock (NQ: JSPR - The Chronicle-Journal
Jasper Therapeutics stock maintains outperform rating at Citizens By Investing.com - Investing.com Canada
JSPR Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):